advertisement
Several clinical and experimental studies have demonstrated that ocular surface disease is common in glaucoma patients receiving chronic glaucoma drops, and that the preservatives in these drops play a major role in the occurrence of ocular surface disease. These ocular surface changes may induce both symptoms reported by the patients and anterior segment clinical signs, and should be systematically assessed by history and exam in all glaucoma patients. In these patients with ocular surface disease, reducing the amount of preservatives administered to the eye should be strived for, rather than adding additional eye drops to alleviate or mask the side effects of the glaucoma drops.
Centre hospitalier universitaire, boulevard de la Chantourne, 38700 La Tronche, France. Electronic address: faptel@chu-grenoble.fr.
Full article11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
2.1 Conjunctiva (Part of: 2 Anatomical structures in glaucoma)
2.3 Sclera (Part of: 2 Anatomical structures in glaucoma)